Global EditionASIA 中文雙語Fran?ais
    World
    Home / World / Americas

    US: AstraZeneca results may have included outdated info

    Updated: 2021-03-24 04:06
    Share
    Share - WeChat
    [Photo/Agencies]

    WASHINGTON — AstraZeneca may have included “outdated information” in touting the effectiveness of its COVID-19 vaccine in a U.S. study, federal health officials said Tuesday in an unusual public rift that could further erode confidence in the shot.

    In response, AstraZeneca said that it is working on more up-to-date information and that the more recent findings are consistent with the earlier ones. It promised an update within 48 hours.

    It was not clear exactly what concerns U.S. health officials have. But the unprecedented tension erupted just hours after AstraZeneca released information it hoped would help settle lingering questions about the effectiveness of a vaccine that is being widely used in Europe and other parts of the world and is about to be considered for use in the U.S.

    The company announced on Monday that a predominantly U.S. study of 32,000 volunteers showed its vaccine was 79% effective in preventing symptomatic COVID-19 disease. It also stressed there were no severe illnesses or hospitalizations among volunteers given the vaccine, compared with five cases among those given dummy shots.

    But shortly after midnight, the National Institutes of Health issued a statement saying the independent monitors that oversee the study had “expressed concern that AstraZeneca may have included outdated information from that trial, which may have provided an incomplete view of the efficacy data.” The NIH urged the company to “ensure the most accurate, up-to-date efficacy data be made public as quickly as possible.” Outside experts were surprised and puzzled by the spat. But they noted that ultimately the Food and Drug Administration will scrutinize all the data before deciding whether AstraZeneca's vaccine can be rolled out in the U.S. “It would seem that whatever this communication misstep is, at the end of the day the data will have to stand for itself,” said Dr. Jesse Goodman of Georgetown University, a former FDA vaccine chief.

    The NIH's Dr. Anthony Fauci told ABC's “Good Morning America” that the incident “really is what you call an unforced error" and that he expects the discrepancy to be straightened out.

    Fauci also said the episode shows the U.S. regulatory system is working: “The data and safety monitoring board picking up this discrepancy was an example of a safeguard.” But that nitty-gritty seldom is seen by the public, something now exposed by the extraordinary microscope being applied to development of the world's COVID-19 vaccines.

    Every vaccine trial is overseen by a “data and safety monitoring board,” or DSMB. These boards include scientists and statisticians who are experts in their fields but have no ties to either the government or the vaccine makers.

    In the AstraZeneca study, just like studies of the other vaccines in use, some participants get the real vaccine and the rest get dummy shots, and neither they nor their doctors know which is which. Only the DSMB has the power to unlock the code of who got which and peek at how the volunteers are faring before a study is finished.

    The DSMB watches for safety concerns and also deems when the study has met pre-determined endpoints showing it's time for an effectiveness calculation. It was the NIH-appointed DSMB that raised the concerns about AstraZeneca's data.

    On Tuesday, AstraZeneca said that the data it first released included COVID-19 cases that occurred up to Feb. 17, as the study rules specified, and that it is continuing to analyze cases that have occurred since then. It said a preliminary analysis of more recent data was consistent with what it had already reported.

    It is common for companies developing COVID-19 vaccines to release early data and to continue studying results as they come in. Some experts had hoped that Monday's AstraZeneca announcement would help rebuild public confidence in the shot around the world.

    The vaccine is used widely in Britain, across the European continent and in other countries, but its rollout was troubled by inconsistent study reports about its effectiveness, and then last week a scare about blood clots that had some countries temporarily pausing inoculations.

    The U.S. study findings announced by AstraZeneca were consistent with studies from elsewhere — and real-world use in Britain — that found the vaccine offers good protection against the worst COVID-19 has to offer. But company executives refused repeated requests from reporters to provide a breakdown of the 141 COVID-19 cases it was using to make the case for the shot's effectiveness.

    The company has said it aims to file an application with the FDA in the coming weeks.

    Agencies via Xinhua

    Most Viewed in 24 Hours
    Top
    BACK TO THE TOP
    English
    Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
    License for publishing multimedia online 0108263

    Registration Number: 130349
    FOLLOW US
    97人妻无码一区二区精品免费| 亚洲中文字幕无码久久精品1| 伊人久久无码中文字幕| 18禁超污无遮挡无码免费网站| 亚洲国产精品成人AV无码久久综合影院| 四虎影视无码永久免费| 中文字幕人妻丝袜乱一区三区| 午夜福利无码不卡在线观看 | 日韩无码系列综合区| 亚洲av无码成h人动漫无遮挡| 天堂中文8资源在线8| 久久中文字幕精品| 精品无码人妻一区二区三区不卡| 亚洲2022国产成人精品无码区 | 亚洲 无码 在线 专区| 亚洲中文字幕伊人久久无码| 无码av中文一二三区| 国产日韩精品无码区免费专区国产 | 成人无码区免费A∨直播| 久久婷婷综合中文字幕| 国产高新无码在线观看| 亚洲精品无码久久一线| 亚洲美日韩Av中文字幕无码久久久妻妇| 日韩精品中文字幕无码一区| 日韩AV无码一区二区三区不卡毛片 | 国产亚洲精品无码拍拍拍色欲| 中文字幕亚洲综合久久菠萝蜜 | 亚洲乱码无码永久不卡在线| 欧美日韩中文国产一区发布| 久久精品无码一区二区无码| 欧美亚洲精品中文字幕乱码免费高清| 亚洲中文字幕无码爆乳av中文| 国产精品无码av在线播放| 亚洲中文字幕无码久久精品1 | 亚洲中文久久精品无码ww16| 最近中文字幕电影大全免费版| 无码精品蜜桃一区二区三区WW| 国产精品无码无在线观看| 伊人久久精品无码二区麻豆| 精品无码一区二区三区在线| 日本精品久久久久中文字幕8|